Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kronos Bio Inc
(NQ:
KRON
)
1.050
+0.059 (+5.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kronos Bio Inc
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
August 08, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
July 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
May 22, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
May 21, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports First-Quarter 2024 Financial Results
May 09, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
March 21, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
March 07, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
March 05, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
February 27, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
January 25, 2024
Company eliminates three executive officer roles and appoints new Executive Leadership team
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
December 18, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
November 27, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
November 13, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
November 02, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
November 02, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
October 27, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
October 13, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
October 04, 2023
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
August 17, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
August 08, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
June 06, 2023
Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences
June 01, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
May 10, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
April 24, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Changes to Board of Directors
April 11, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
March 15, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
February 28, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.